ARRY-162

ARRY-162 is a selective, potent inhibitor of MEK and cellular pERK with IC50 of 12 nM and 11 nM, respectively. ARRY-162 (MEK-162) shows ex vivo inhibition of cytokine production such as IL-1, TNF and IL-6 in clinical trials. MEK signaling pathway acts as a central axis in the proliferation of different tumors including melanoma, non-small cell lung, head/neck and pancreatic cancers. And MEK inhibition is an important therapeutic strategy in treating cancer either alone or in combination with other agents. ARRY-162 has the potential to treat a range of malignant diseases.